drugset / Trial / NCT05633914
Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is looking to see whether the combination of Tucidinostat and nab-paclitaxel is safe and effective in participants with advanced HR+/HER2- breast cancer.
Timeline
- Start
- 2023-02-07
- Primary completion
- 2024-12-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |